J Mult Scler Neuroimmunol.
2023 Dec;14(2):87-98. 10.59578/jmsni.2023.14.2.87.
National Consensus Guidance for the Diagnosis and Management of Adult Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
- Affiliations
-
- 1Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul Korea
- 2Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea
- 3Department of Neurology, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, Korea
- 4Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
- 5Department of Neurology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 6Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
- 7Department of Neurology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea
- 8Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 9Parkminsu Neurology Clinic, Daegu, Korea
- 10Department of Neurology, Soonchunhyang University Hospital Cheonan, Soonchunhyang University College of Medicine,Cheonan, Korea
- 11Department of Neurology, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea
- 12Department of Neurology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
- 13Department of Neurology, Jeonju Hospital, Jeonju, Korea
- 14Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- KMID: 2561985
- DOI: http://doi.org/10.59578/jmsni.2023.14.2.87
Abstract
- Background
The emergence of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), defined by the presence of antibodies against myelin oligodendrocyte glycoprotein (MOG), has prompted the need for standardized management approaches. Given the current absence of high-level evidence, we aimed to develop consensus-based guidance for the management of MOGAD.
Methods
The Korean Society of Neuroimmunology established a task force comprising a panel of 13 experts, and the RAND/UCLA appropriateness methodology was adopted. Definitions were developed for core clinical manifestation, acute stage, relapse, and persistent MOG-IgG seropositivity. Based on extensive review of the literature, initial guidance statements on four key topics were developed. Two rounds of anonymous votes were conducted to achieve consensus on guidance statements, with modifications based on panel input.
Results
Comprehensive guidance statements were developed covering MOG antibody assay and diagnosis, acute treatment, and long-term immunotherapy for MOGAD.
Conclusion
This guidance is a national formal consensus of MOGAD experts intended to serve as a valuable guide for clinicians managing Korean adults with MOGAD.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of NMOSD with Double Seropositive for AQP-4 and MOG Antibodies
- Immunocytochemical localization of myelin basic protein, proteolipid protein and myelin-associated glycoprotein in human oligodendrocyte in culture
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Review
- Clinical and Radiological Features of Myelin Oligodendrocyte Glycoprotein-Associated Myelitis in Adults
- A Case of Post-Infective Myelin-Oligodendrocyte Glycoprotein Antibody-Associated Disease
